Distocur 34 mg/ml Oral Suspension for Cattle and Sheep

Country: United Kingdom

Language: English

Source: VMD (Veterinary Medicines Directorate)

Buy It Now

Active ingredient:

Oxyclozanide

Available from:

Boehringer Ingelheim Animal Health UK Ltd

ATC code:

QP52AG06

INN (International Name):

Oxyclozanide

Pharmaceutical form:

Oral suspension

Prescription type:

POM-VPS -Prescription Only Medicine – Veterinarian, Pharmacist, Suitably Qualified Person

Therapeutic group:

Cattle

Therapeutic area:

Anthelmintic flukicide

Authorization status:

Authorized

Authorization date:

2016-11-16

Summary of Product characteristics

                                Revised: July 2019
AN: 00598/2018
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Distocur 34 mg/ml Oral Suspension for Cattle and Sheep
Distocur.vet 34 mg/ml Oral Suspension for Cattle (DK, NO, SE)
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each ml contains:
ACTIVE SUBSTANCE:
Oxyclozanide ………………………………………… 34.0 mg
EXCIPIENTS:
Methyl parahydroxybenzoate (E218)…………………. 1.35 mg
Propyl parahydroxybenzoate …………………………. 0.15 mg
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Oral suspension.
Whitish to beige suspension.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Cattle and Sheep.
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Treatment of infections caused by the adult stage of_ Fasciola
hepatica,_ sensitive to
oxyclozanide.
Elimination of gravid tapeworm segments (_Moniezia spp_.).
4.3
CONTRAINDICATIONS
Do not use in cases of known hypersensitivity to the active substance
or to any of the
excipients.
Page 1 of 6
Revised: July 2019
AN: 00598/2018
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
To date no resistance to oxyclozanide has been reported. Use of the
product should
be based on local (regional, farm) epidemiological information about
susceptibility of
trematodes and recommendations on how to limit further selection for
resistance to
anthelmintics.
Care should be taken to avoid the following practices because they
increase the risk
of development of resistance and could ultimately result in
ineffective therapy:
-
Too frequent and repeated use of anthelmintics from the same class,
over an
extended period of time.
-
Underdosing, which may be due to underestimation of body weight,
misadministration of the product or lack of calibration of the dosing
device (if
any).
Suspected clinical cases of resistance to anthelmintics should be
further investigated
using appropriate tests (e.g. Faecal Egg Count Reduction Test). Where
the results of
the test(s) strongly suggest resistance to a particular
                                
                                Read the complete document
                                
                            

Search alerts related to this product